nodes	percent_of_prediction	percent_of_DWPC	metapath
Daunorubicin—Epirubicin—testicular cancer	0.136	0.519	CrCtD
Daunorubicin—Doxorubicin—testicular cancer	0.125	0.481	CrCtD
Daunorubicin—Anthracyclines—Epirubicin—testicular cancer	0.0908	0.271	CiPCiCtD
Daunorubicin—Anthracyclines—Doxorubicin—testicular cancer	0.084	0.251	CiPCiCtD
Daunorubicin—Topoisomerase Inhibitors—Etoposide—testicular cancer	0.0689	0.206	CiPCiCtD
Daunorubicin—Topoisomerase Inhibitors—Epirubicin—testicular cancer	0.0474	0.142	CiPCiCtD
Daunorubicin—Topoisomerase Inhibitors—Doxorubicin—testicular cancer	0.0439	0.131	CiPCiCtD
Daunorubicin—Doxorubicin—Epirubicin—testicular cancer	0.0289	0.173	CrCrCtD
Daunorubicin—Idarubicin—Epirubicin—testicular cancer	0.0289	0.173	CrCrCtD
Daunorubicin—Valrubicin—Epirubicin—testicular cancer	0.0289	0.173	CrCrCtD
Daunorubicin—Idarubicin—Doxorubicin—testicular cancer	0.0268	0.16	CrCrCtD
Daunorubicin—Valrubicin—Doxorubicin—testicular cancer	0.0268	0.16	CrCrCtD
Daunorubicin—Epirubicin—Doxorubicin—testicular cancer	0.0268	0.16	CrCrCtD
Daunorubicin—YWHAG—Epirubicin—testicular cancer	0.0207	0.115	CbGbCtD
Daunorubicin—NR5A1—Vinblastine—testicular cancer	0.0179	0.0994	CbGbCtD
Daunorubicin—TOP2B—Etoposide—testicular cancer	0.0161	0.0896	CbGbCtD
Daunorubicin—YWHAG—Doxorubicin—testicular cancer	0.011	0.0611	CbGbCtD
Daunorubicin—ABCC6—Dactinomycin—testicular cancer	0.0109	0.0606	CbGbCtD
Daunorubicin—ABCC6—Vinblastine—testicular cancer	0.00684	0.038	CbGbCtD
Daunorubicin—ABCC6—Cisplatin—testicular cancer	0.00627	0.0348	CbGbCtD
Daunorubicin—ABCC6—Etoposide—testicular cancer	0.00616	0.0342	CbGbCtD
Daunorubicin—NR5A1—corpus luteum—testicular cancer	0.00498	0.315	CbGeAlD
Daunorubicin—ABCC10—Etoposide—testicular cancer	0.00471	0.0261	CbGbCtD
Daunorubicin—XDH—Carboplatin—testicular cancer	0.00458	0.0254	CbGbCtD
Daunorubicin—POR—Doxorubicin—testicular cancer	0.00457	0.0254	CbGbCtD
Daunorubicin—NR5A1—seminiferous tubule of testis—testicular cancer	0.00422	0.267	CbGeAlD
Daunorubicin—TOP2A—Epirubicin—testicular cancer	0.00421	0.0234	CbGbCtD
Daunorubicin—ABCC6—Doxorubicin—testicular cancer	0.0042	0.0233	CbGbCtD
Daunorubicin—XDH—Cisplatin—testicular cancer	0.00392	0.0217	CbGbCtD
Daunorubicin—TOP2A—Etoposide—testicular cancer	0.00328	0.0182	CbGbCtD
Daunorubicin—ABCC1—Dactinomycin—testicular cancer	0.00322	0.0179	CbGbCtD
Daunorubicin—ABCC10—Doxorubicin—testicular cancer	0.00321	0.0178	CbGbCtD
Daunorubicin—ABCC10—Methotrexate—testicular cancer	0.00311	0.0173	CbGbCtD
Daunorubicin—ABCB11—Vinblastine—testicular cancer	0.00284	0.0158	CbGbCtD
Daunorubicin—XDH—Doxorubicin—testicular cancer	0.00263	0.0146	CbGbCtD
Daunorubicin—NR5A1—Ovarian Infertility Genes—DAZL—testicular cancer	0.00246	0.346	CbGpPWpGaD
Daunorubicin—ABCC1—Epirubicin—testicular cancer	0.00233	0.0129	CbGbCtD
Daunorubicin—TOP2A—Doxorubicin—testicular cancer	0.00224	0.0124	CbGbCtD
Daunorubicin—NR5A1—Transcriptional regulation of pluripotent stem cells—PRDM14—testicular cancer	0.00222	0.312	CbGpPWpGaD
Daunorubicin—ABCG2—Dactinomycin—testicular cancer	0.00216	0.012	CbGbCtD
Daunorubicin—ABCC1—Vinblastine—testicular cancer	0.00202	0.0112	CbGbCtD
Daunorubicin—SLC22A2—Vinblastine—testicular cancer	0.00183	0.0101	CbGbCtD
Daunorubicin—ABCC1—Etoposide—testicular cancer	0.00182	0.0101	CbGbCtD
Daunorubicin—CYP1B1—Doxorubicin—testicular cancer	0.00174	0.00968	CbGbCtD
Daunorubicin—ABCB11—Doxorubicin—testicular cancer	0.00174	0.00968	CbGbCtD
Daunorubicin—SLC22A2—Cisplatin—testicular cancer	0.00168	0.00931	CbGbCtD
Daunorubicin—ABCC2—Carboplatin—testicular cancer	0.0016	0.00889	CbGbCtD
Daunorubicin—ABCC2—Vinblastine—testicular cancer	0.00149	0.00829	CbGbCtD
Daunorubicin—ABCG2—Carboplatin—testicular cancer	0.00145	0.00804	CbGbCtD
Daunorubicin—CYP3A5—Ifosfamide—testicular cancer	0.00141	0.00782	CbGbCtD
Daunorubicin—ABCC2—Cisplatin—testicular cancer	0.00137	0.0076	CbGbCtD
Daunorubicin—ABCC2—Etoposide—testicular cancer	0.00135	0.00747	CbGbCtD
Daunorubicin—ABCC1—Doxorubicin—testicular cancer	0.00124	0.00688	CbGbCtD
Daunorubicin—ABCG2—Cisplatin—testicular cancer	0.00124	0.00687	CbGbCtD
Daunorubicin—ABCG2—Etoposide—testicular cancer	0.00122	0.00675	CbGbCtD
Daunorubicin—ABCC1—Methotrexate—testicular cancer	0.0012	0.00666	CbGbCtD
Daunorubicin—ABCC2—Doxorubicin—testicular cancer	0.000917	0.00509	CbGbCtD
Daunorubicin—ABCC2—Methotrexate—testicular cancer	0.000889	0.00493	CbGbCtD
Daunorubicin—ABCG2—Doxorubicin—testicular cancer	0.000829	0.0046	CbGbCtD
Daunorubicin—ABCG2—Methotrexate—testicular cancer	0.000804	0.00446	CbGbCtD
Daunorubicin—ABCB1—Dactinomycin—testicular cancer	0.000777	0.00431	CbGbCtD
Daunorubicin—CYP3A5—Etoposide—testicular cancer	0.000674	0.00374	CbGbCtD
Daunorubicin—CYP3A4—Ifosfamide—testicular cancer	0.00055	0.00305	CbGbCtD
Daunorubicin—CYP1A2—Etoposide—testicular cancer	0.000501	0.00278	CbGbCtD
Daunorubicin—ABCB1—Vinblastine—testicular cancer	0.000487	0.0027	CbGbCtD
Daunorubicin—ABCB1—Cisplatin—testicular cancer	0.000446	0.00248	CbGbCtD
Daunorubicin—ABCB1—Etoposide—testicular cancer	0.000439	0.00243	CbGbCtD
Daunorubicin—NR5A1—gonad—testicular cancer	0.000358	0.0226	CbGeAlD
Daunorubicin—TOP2B—embryo—testicular cancer	0.000335	0.0212	CbGeAlD
Daunorubicin—YWHAG—seminal vesicle—testicular cancer	0.000327	0.0207	CbGeAlD
Daunorubicin—TOP2B—seminal vesicle—testicular cancer	0.000315	0.02	CbGeAlD
Daunorubicin—ABCB1—Doxorubicin—testicular cancer	0.000299	0.00166	CbGbCtD
Daunorubicin—CYP3A4—Vinblastine—testicular cancer	0.000292	0.00162	CbGbCtD
Daunorubicin—NR5A1—female gonad—testicular cancer	0.000291	0.0184	CbGeAlD
Daunorubicin—ABCB1—Methotrexate—testicular cancer	0.00029	0.00161	CbGbCtD
Daunorubicin—CYP3A4—Etoposide—testicular cancer	0.000263	0.00146	CbGbCtD
Daunorubicin—NR5A1—testis—testicular cancer	0.000258	0.0163	CbGeAlD
Daunorubicin—POR—seminal vesicle—testicular cancer	0.000249	0.0157	CbGeAlD
Daunorubicin—YWHAG—gonad—testicular cancer	0.000236	0.015	CbGeAlD
Daunorubicin—TOP2B—Teniposide—Etoposide—testicular cancer	0.000232	0.323	CbGdCrCtD
Daunorubicin—TOP2B—gonad—testicular cancer	0.000228	0.0144	CbGeAlD
Daunorubicin—ABCC6—Podofilox—Etoposide—testicular cancer	0.000207	0.288	CbGdCrCtD
Daunorubicin—ABCC10—seminal vesicle—testicular cancer	0.000197	0.0125	CbGeAlD
Daunorubicin—YWHAG—female gonad—testicular cancer	0.000192	0.0122	CbGeAlD
Daunorubicin—TOP2B—female gonad—testicular cancer	0.000185	0.0117	CbGeAlD
Daunorubicin—CYP3A4—Doxorubicin—testicular cancer	0.000179	0.000995	CbGbCtD
Daunorubicin—NR5A1—Developmental Biology—PRDM14—testicular cancer	0.000177	0.025	CbGpPWpGaD
Daunorubicin—YWHAG—testis—testicular cancer	0.00017	0.0108	CbGeAlD
Daunorubicin—TOP2B—testis—testicular cancer	0.000164	0.0104	CbGeAlD
Daunorubicin—ABCB11—testis—testicular cancer	0.000162	0.0103	CbGeAlD
Daunorubicin—YWHAG—LKB1 signaling events—STK11—testicular cancer	0.00015	0.0211	CbGpPWpGaD
Daunorubicin—POR—female gonad—testicular cancer	0.000146	0.00924	CbGeAlD
Daunorubicin—ABCC10—gonad—testicular cancer	0.000143	0.00903	CbGeAlD
Daunorubicin—ABCC1—seminal vesicle—testicular cancer	0.000139	0.00883	CbGeAlD
Daunorubicin—TOP2A—female gonad—testicular cancer	0.000136	0.00862	CbGeAlD
Daunorubicin—POR—testis—testicular cancer	0.000129	0.0082	CbGeAlD
Daunorubicin—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000125	0.0176	CbGpPWpGaD
Daunorubicin—ABCC6—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000125	0.0176	CbGpPWpGaD
Daunorubicin—YWHAG—lymph node—testicular cancer	0.000123	0.00782	CbGeAlD
Daunorubicin—TOP2A—testis—testicular cancer	0.000121	0.00764	CbGeAlD
Daunorubicin—TOP2B—lymph node—testicular cancer	0.000119	0.00753	CbGeAlD
Daunorubicin—ABCC10—female gonad—testicular cancer	0.000116	0.00733	CbGeAlD
Daunorubicin—ABCG2—seminal vesicle—testicular cancer	0.000115	0.00731	CbGeAlD
Daunorubicin—CYP1B1—gonad—testicular cancer	0.000112	0.0071	CbGeAlD
Daunorubicin—ABCC10—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000109	0.0154	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle—MAD1L1—testicular cancer	0.000109	0.0153	CbGpPWpGaD
Daunorubicin—ABCC2—NRF2 pathway—SLC2A6—testicular cancer	0.000105	0.0148	CbGpPWpGaD
Daunorubicin—ABCC10—testis—testicular cancer	0.000103	0.00651	CbGeAlD
Daunorubicin—POR—lymph node—testicular cancer	9.38e-05	0.00594	CbGeAlD
Daunorubicin—CYP1B1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	9.17e-05	0.0129	CbGpPWpGaD
Daunorubicin—CYP1B1—female gonad—testicular cancer	9.11e-05	0.00577	CbGeAlD
Daunorubicin—ABCC1—Arachidonic acid metabolism—HPGDS—testicular cancer	8.87e-05	0.0125	CbGpPWpGaD
Daunorubicin—TOP2A—lymph node—testicular cancer	8.75e-05	0.00554	CbGeAlD
Daunorubicin—CYP1B1—Arachidonic acid metabolism—HPGDS—testicular cancer	8.58e-05	0.0121	CbGpPWpGaD
Daunorubicin—ABCC2—testis—testicular cancer	8.25e-05	0.00522	CbGeAlD
Daunorubicin—ABCC1—female gonad—testicular cancer	8.19e-05	0.00519	CbGeAlD
Daunorubicin—CYP1B1—testis—testicular cancer	8.08e-05	0.00512	CbGeAlD
Daunorubicin—ABCC10—lymph node—testicular cancer	7.45e-05	0.00472	CbGeAlD
Daunorubicin—ABCC1—testis—testicular cancer	7.27e-05	0.0046	CbGeAlD
Daunorubicin—YWHAG—Cell Cycle—KITLG—testicular cancer	6.97e-05	0.0098	CbGpPWpGaD
Daunorubicin—ABCG2—female gonad—testicular cancer	6.78e-05	0.00429	CbGeAlD
Daunorubicin—CYP1A1—female gonad—testicular cancer	6.44e-05	0.00408	CbGeAlD
Daunorubicin—CYP3A5—female gonad—testicular cancer	6.3e-05	0.00399	CbGeAlD
Daunorubicin—ABCB1—embryo—testicular cancer	6.06e-05	0.00384	CbGeAlD
Daunorubicin—TOP2A—Retinoblastoma (RB) in Cancer—H2AFZ—testicular cancer	6.02e-05	0.00846	CbGpPWpGaD
Daunorubicin—ABCG2—testis—testicular cancer	6.01e-05	0.00381	CbGeAlD
Daunorubicin—ABCC2—lymph node—testicular cancer	5.98e-05	0.00379	CbGeAlD
Daunorubicin—TOP2A—Vindesine—Vinblastine—testicular cancer	5.94e-05	0.0828	CbGdCrCtD
Daunorubicin—CYP1B1—lymph node—testicular cancer	5.86e-05	0.00371	CbGeAlD
Daunorubicin—ABCB1—seminal vesicle—testicular cancer	5.69e-05	0.00361	CbGeAlD
Daunorubicin—SLC22A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	5.69e-05	0.00801	CbGpPWpGaD
Daunorubicin—CYP1A1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	5.65e-05	0.00795	CbGpPWpGaD
Daunorubicin—NR5A1—Gene Expression—DNMT3L—testicular cancer	5.61e-05	0.00789	CbGpPWpGaD
Daunorubicin—CYP1A1—Arachidonic acid metabolism—HPGDS—testicular cancer	5.29e-05	0.00743	CbGpPWpGaD
Daunorubicin—ABCC1—lymph node—testicular cancer	5.27e-05	0.00334	CbGeAlD
Daunorubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—testicular cancer	5.12e-05	0.0072	CbGpPWpGaD
Daunorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	4.39e-05	0.00617	CbGpPWpGaD
Daunorubicin—ABCG2—lymph node—testicular cancer	4.36e-05	0.00276	CbGeAlD
Daunorubicin—CYP1A1—lymph node—testicular cancer	4.14e-05	0.00262	CbGeAlD
Daunorubicin—ABCB1—gonad—testicular cancer	4.12e-05	0.00261	CbGeAlD
Daunorubicin—TOP2A—Vinorelbine—Vinblastine—testicular cancer	3.75e-05	0.0522	CbGdCrCtD
Daunorubicin—TOP2A—Podofilox—Etoposide—testicular cancer	3.74e-05	0.0522	CbGdCrCtD
Daunorubicin—TOP2A—Teniposide—Etoposide—testicular cancer	3.74e-05	0.0522	CbGdCrCtD
Daunorubicin—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	3.64e-05	0.00512	CbGpPWpGaD
Daunorubicin—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	3.6e-05	0.00507	CbGpPWpGaD
Daunorubicin—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	3.37e-05	0.00474	CbGpPWpGaD
Daunorubicin—ABCC2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.36e-05	0.00473	CbGpPWpGaD
Daunorubicin—ABCB1—female gonad—testicular cancer	3.34e-05	0.00212	CbGeAlD
Daunorubicin—ABCC1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.32e-05	0.00467	CbGpPWpGaD
Daunorubicin—TOP2A—Vincristine—Vinblastine—testicular cancer	3.2e-05	0.0447	CbGdCrCtD
Daunorubicin—CYP1B1—Biological oxidations—HPGDS—testicular cancer	3.19e-05	0.00449	CbGpPWpGaD
Daunorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	3.19e-05	0.00448	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle, Mitotic—MAD1L1—testicular cancer	3.18e-05	0.00448	CbGpPWpGaD
Daunorubicin—ABCB1—testis—testicular cancer	2.97e-05	0.00188	CbGeAlD
Daunorubicin—ABCG2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	2.92e-05	0.00411	CbGpPWpGaD
Daunorubicin—SLC22A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	2.89e-05	0.00407	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle—MAD1L1—testicular cancer	2.85e-05	0.004	CbGpPWpGaD
Daunorubicin—TOP2A—Cell Cycle, Mitotic—MAD1L1—testicular cancer	2.23e-05	0.00313	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle, Mitotic—H2AFZ—testicular cancer	2.22e-05	0.00312	CbGpPWpGaD
Daunorubicin—ABCB1—lymph node—testicular cancer	2.15e-05	0.00136	CbGeAlD
Daunorubicin—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	2.14e-05	0.00302	CbGpPWpGaD
Daunorubicin—NR5A1—Developmental Biology—MMP2—testicular cancer	2.13e-05	0.003	CbGpPWpGaD
Daunorubicin—CYP3A5—Biological oxidations—HPGDS—testicular cancer	2.08e-05	0.00293	CbGpPWpGaD
Daunorubicin—TOP2A—Cell Cycle—MAD1L1—testicular cancer	1.99e-05	0.0028	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle—H2AFZ—testicular cancer	1.98e-05	0.00279	CbGpPWpGaD
Daunorubicin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	1.97e-05	0.00277	CbGpPWpGaD
Daunorubicin—CYP1A1—Biological oxidations—HPGDS—testicular cancer	1.97e-05	0.00277	CbGpPWpGaD
Daunorubicin—NR5A1—Gene Expression—H2AFZ—testicular cancer	1.96e-05	0.00276	CbGpPWpGaD
Daunorubicin—TOP2A—Doxorubicin—Epirubicin—testicular cancer	1.95e-05	0.0272	CbGdCrCtD
Daunorubicin—TOP2A—Idarubicin—Epirubicin—testicular cancer	1.95e-05	0.0272	CbGdCrCtD
Daunorubicin—Asthenia—Dactinomycin—testicular cancer	1.93e-05	0.000586	CcSEcCtD
Daunorubicin—Dysphagia—Epirubicin—testicular cancer	1.92e-05	0.000582	CcSEcCtD
Daunorubicin—Dysuria—Methotrexate—testicular cancer	1.92e-05	0.000582	CcSEcCtD
Daunorubicin—Neutropenia—Methotrexate—testicular cancer	1.92e-05	0.000582	CcSEcCtD
Daunorubicin—Dehydration—Doxorubicin—testicular cancer	1.92e-05	0.00058	CcSEcCtD
Daunorubicin—Thrombocytopenia—Etoposide—testicular cancer	1.91e-05	0.000578	CcSEcCtD
Daunorubicin—Tachycardia—Etoposide—testicular cancer	1.9e-05	0.000577	CcSEcCtD
Daunorubicin—Dyspnoea—Cisplatin—testicular cancer	1.9e-05	0.000575	CcSEcCtD
Daunorubicin—Dry skin—Doxorubicin—testicular cancer	1.89e-05	0.000571	CcSEcCtD
Daunorubicin—Hyperhidrosis—Etoposide—testicular cancer	1.89e-05	0.000571	CcSEcCtD
Daunorubicin—Angina pectoris—Epirubicin—testicular cancer	1.87e-05	0.000567	CcSEcCtD
Daunorubicin—Anorexia—Etoposide—testicular cancer	1.86e-05	0.000563	CcSEcCtD
Daunorubicin—Decreased appetite—Cisplatin—testicular cancer	1.85e-05	0.000561	CcSEcCtD
Daunorubicin—Diarrhoea—Dactinomycin—testicular cancer	1.84e-05	0.000559	CcSEcCtD
Daunorubicin—Vomiting—Bleomycin—testicular cancer	1.84e-05	0.000557	CcSEcCtD
Daunorubicin—Depression—Methotrexate—testicular cancer	1.83e-05	0.000553	CcSEcCtD
Daunorubicin—Pancytopenia—Epirubicin—testicular cancer	1.83e-05	0.000553	CcSEcCtD
Daunorubicin—Rash—Bleomycin—testicular cancer	1.82e-05	0.000552	CcSEcCtD
Daunorubicin—Gastritis—Doxorubicin—testicular cancer	1.82e-05	0.000552	CcSEcCtD
Daunorubicin—Pain—Cisplatin—testicular cancer	1.82e-05	0.000551	CcSEcCtD
Daunorubicin—Dermatitis—Bleomycin—testicular cancer	1.82e-05	0.000551	CcSEcCtD
Daunorubicin—Hypersensitivity—Ifosfamide—testicular cancer	1.82e-05	0.000551	CcSEcCtD
Daunorubicin—TOP2A—Idarubicin—Doxorubicin—testicular cancer	1.81e-05	0.0252	CbGdCrCtD
Daunorubicin—TOP2A—Epirubicin—Doxorubicin—testicular cancer	1.81e-05	0.0252	CbGdCrCtD
Daunorubicin—Renal failure—Methotrexate—testicular cancer	1.8e-05	0.000545	CcSEcCtD
Daunorubicin—Neutropenia—Epirubicin—testicular cancer	1.8e-05	0.000545	CcSEcCtD
Daunorubicin—Dysuria—Epirubicin—testicular cancer	1.8e-05	0.000545	CcSEcCtD
Daunorubicin—Stomatitis—Methotrexate—testicular cancer	1.79e-05	0.000541	CcSEcCtD
Daunorubicin—Conjunctivitis—Methotrexate—testicular cancer	1.78e-05	0.000539	CcSEcCtD
Daunorubicin—Dysphagia—Doxorubicin—testicular cancer	1.78e-05	0.000539	CcSEcCtD
Daunorubicin—Asthenia—Ifosfamide—testicular cancer	1.77e-05	0.000537	CcSEcCtD
Daunorubicin—Feeling abnormal—Cisplatin—testicular cancer	1.76e-05	0.000531	CcSEcCtD
Daunorubicin—Pruritus—Ifosfamide—testicular cancer	1.75e-05	0.000529	CcSEcCtD
Daunorubicin—Dyspnoea—Etoposide—testicular cancer	1.74e-05	0.000527	CcSEcCtD
Daunorubicin—Somnolence—Etoposide—testicular cancer	1.73e-05	0.000525	CcSEcCtD
Daunorubicin—Angina pectoris—Doxorubicin—testicular cancer	1.73e-05	0.000525	CcSEcCtD
Daunorubicin—Nausea—Bleomycin—testicular cancer	1.72e-05	0.00052	CcSEcCtD
Daunorubicin—Vomiting—Dactinomycin—testicular cancer	1.71e-05	0.000519	CcSEcCtD
Daunorubicin—Rash—Dactinomycin—testicular cancer	1.7e-05	0.000515	CcSEcCtD
Daunorubicin—Decreased appetite—Etoposide—testicular cancer	1.7e-05	0.000514	CcSEcCtD
Daunorubicin—Diarrhoea—Ifosfamide—testicular cancer	1.69e-05	0.000512	CcSEcCtD
Daunorubicin—Pancytopenia—Doxorubicin—testicular cancer	1.69e-05	0.000512	CcSEcCtD
Daunorubicin—ABCB11—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.69e-05	0.00237	CbGpPWpGaD
Daunorubicin—Renal failure—Epirubicin—testicular cancer	1.69e-05	0.00051	CcSEcCtD
Daunorubicin—Body temperature increased—Cisplatin—testicular cancer	1.68e-05	0.00051	CcSEcCtD
Daunorubicin—Fatigue—Etoposide—testicular cancer	1.68e-05	0.000509	CcSEcCtD
Daunorubicin—Neuropathy peripheral—Epirubicin—testicular cancer	1.68e-05	0.000509	CcSEcCtD
Daunorubicin—Stomatitis—Epirubicin—testicular cancer	1.67e-05	0.000506	CcSEcCtD
Daunorubicin—Pain—Etoposide—testicular cancer	1.67e-05	0.000505	CcSEcCtD
Daunorubicin—Constipation—Etoposide—testicular cancer	1.67e-05	0.000505	CcSEcCtD
Daunorubicin—Conjunctivitis—Epirubicin—testicular cancer	1.67e-05	0.000505	CcSEcCtD
Daunorubicin—Dysuria—Doxorubicin—testicular cancer	1.66e-05	0.000504	CcSEcCtD
Daunorubicin—Neutropenia—Doxorubicin—testicular cancer	1.66e-05	0.000504	CcSEcCtD
Daunorubicin—Dizziness—Ifosfamide—testicular cancer	1.63e-05	0.000495	CcSEcCtD
Daunorubicin—Sinusitis—Epirubicin—testicular cancer	1.61e-05	0.000487	CcSEcCtD
Daunorubicin—Feeling abnormal—Etoposide—testicular cancer	1.61e-05	0.000487	CcSEcCtD
Daunorubicin—Nausea—Dactinomycin—testicular cancer	1.6e-05	0.000485	CcSEcCtD
Daunorubicin—Gastrointestinal pain—Etoposide—testicular cancer	1.6e-05	0.000483	CcSEcCtD
Daunorubicin—Visual impairment—Methotrexate—testicular cancer	1.59e-05	0.00048	CcSEcCtD
Daunorubicin—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	1.58e-05	0.00222	CbGpPWpGaD
Daunorubicin—Vomiting—Ifosfamide—testicular cancer	1.57e-05	0.000476	CcSEcCtD
Daunorubicin—Hypersensitivity—Cisplatin—testicular cancer	1.57e-05	0.000475	CcSEcCtD
Daunorubicin—Renal failure—Doxorubicin—testicular cancer	1.56e-05	0.000472	CcSEcCtD
Daunorubicin—Rash—Ifosfamide—testicular cancer	1.56e-05	0.000472	CcSEcCtD
Daunorubicin—Dermatitis—Ifosfamide—testicular cancer	1.56e-05	0.000471	CcSEcCtD
Daunorubicin—Neuropathy peripheral—Doxorubicin—testicular cancer	1.56e-05	0.000471	CcSEcCtD
Daunorubicin—TOP2A—Cell Cycle, Mitotic—H2AFZ—testicular cancer	1.55e-05	0.00218	CbGpPWpGaD
Daunorubicin—Urticaria—Etoposide—testicular cancer	1.55e-05	0.000469	CcSEcCtD
Daunorubicin—Stomatitis—Doxorubicin—testicular cancer	1.55e-05	0.000468	CcSEcCtD
Daunorubicin—Rhinitis—Epirubicin—testicular cancer	1.54e-05	0.000467	CcSEcCtD
Daunorubicin—Abdominal pain—Etoposide—testicular cancer	1.54e-05	0.000467	CcSEcCtD
Daunorubicin—Body temperature increased—Etoposide—testicular cancer	1.54e-05	0.000467	CcSEcCtD
Daunorubicin—Conjunctivitis—Doxorubicin—testicular cancer	1.54e-05	0.000467	CcSEcCtD
Daunorubicin—Tinnitus—Methotrexate—testicular cancer	1.53e-05	0.000464	CcSEcCtD
Daunorubicin—Asthenia—Cisplatin—testicular cancer	1.53e-05	0.000463	CcSEcCtD
Daunorubicin—Cardiac disorder—Methotrexate—testicular cancer	1.53e-05	0.000462	CcSEcCtD
Daunorubicin—Sinusitis—Doxorubicin—testicular cancer	1.49e-05	0.000451	CcSEcCtD
Daunorubicin—Visual impairment—Epirubicin—testicular cancer	1.48e-05	0.000449	CcSEcCtD
Daunorubicin—Chills—Methotrexate—testicular cancer	1.48e-05	0.000447	CcSEcCtD
Daunorubicin—Nausea—Ifosfamide—testicular cancer	1.47e-05	0.000444	CcSEcCtD
Daunorubicin—Diarrhoea—Cisplatin—testicular cancer	1.46e-05	0.000441	CcSEcCtD
Daunorubicin—Alopecia—Methotrexate—testicular cancer	1.45e-05	0.00044	CcSEcCtD
Daunorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	1.44e-05	0.00203	CbGpPWpGaD
Daunorubicin—Hypersensitivity—Etoposide—testicular cancer	1.44e-05	0.000435	CcSEcCtD
Daunorubicin—Tinnitus—Epirubicin—testicular cancer	1.44e-05	0.000435	CcSEcCtD
Daunorubicin—Erythema—Methotrexate—testicular cancer	1.43e-05	0.000434	CcSEcCtD
Daunorubicin—Cardiac disorder—Epirubicin—testicular cancer	1.43e-05	0.000433	CcSEcCtD
Daunorubicin—Flushing—Epirubicin—testicular cancer	1.43e-05	0.000433	CcSEcCtD
Daunorubicin—Rhinitis—Doxorubicin—testicular cancer	1.43e-05	0.000432	CcSEcCtD
Daunorubicin—Dysgeusia—Methotrexate—testicular cancer	1.4e-05	0.000425	CcSEcCtD
Daunorubicin—Asthenia—Etoposide—testicular cancer	1.4e-05	0.000424	CcSEcCtD
Daunorubicin—TOP2A—Cell Cycle—H2AFZ—testicular cancer	1.39e-05	0.00195	CbGpPWpGaD
Daunorubicin—Back pain—Methotrexate—testicular cancer	1.39e-05	0.000419	CcSEcCtD
Daunorubicin—Chills—Epirubicin—testicular cancer	1.38e-05	0.000418	CcSEcCtD
Daunorubicin—Pruritus—Etoposide—testicular cancer	1.38e-05	0.000418	CcSEcCtD
Daunorubicin—Arrhythmia—Epirubicin—testicular cancer	1.38e-05	0.000416	CcSEcCtD
Daunorubicin—Visual impairment—Doxorubicin—testicular cancer	1.37e-05	0.000416	CcSEcCtD
Daunorubicin—Alopecia—Epirubicin—testicular cancer	1.36e-05	0.000412	CcSEcCtD
Daunorubicin—Vomiting—Cisplatin—testicular cancer	1.35e-05	0.00041	CcSEcCtD
Daunorubicin—Rash—Cisplatin—testicular cancer	1.34e-05	0.000407	CcSEcCtD
Daunorubicin—Dermatitis—Cisplatin—testicular cancer	1.34e-05	0.000406	CcSEcCtD
Daunorubicin—Erythema—Epirubicin—testicular cancer	1.34e-05	0.000406	CcSEcCtD
Daunorubicin—Diarrhoea—Etoposide—testicular cancer	1.34e-05	0.000404	CcSEcCtD
Daunorubicin—Ill-defined disorder—Methotrexate—testicular cancer	1.33e-05	0.000402	CcSEcCtD
Daunorubicin—Tinnitus—Doxorubicin—testicular cancer	1.33e-05	0.000402	CcSEcCtD
Daunorubicin—Anaemia—Methotrexate—testicular cancer	1.32e-05	0.000401	CcSEcCtD
Daunorubicin—Cardiac disorder—Doxorubicin—testicular cancer	1.32e-05	0.0004	CcSEcCtD
Daunorubicin—Flushing—Doxorubicin—testicular cancer	1.32e-05	0.0004	CcSEcCtD
Daunorubicin—Dysgeusia—Epirubicin—testicular cancer	1.31e-05	0.000397	CcSEcCtD
Daunorubicin—Back pain—Epirubicin—testicular cancer	1.3e-05	0.000393	CcSEcCtD
Daunorubicin—Malaise—Methotrexate—testicular cancer	1.29e-05	0.000391	CcSEcCtD
Daunorubicin—Dizziness—Etoposide—testicular cancer	1.29e-05	0.000391	CcSEcCtD
Daunorubicin—Leukopenia—Methotrexate—testicular cancer	1.28e-05	0.000388	CcSEcCtD
Daunorubicin—Chills—Doxorubicin—testicular cancer	1.28e-05	0.000387	CcSEcCtD
Daunorubicin—Arrhythmia—Doxorubicin—testicular cancer	1.27e-05	0.000385	CcSEcCtD
Daunorubicin—ABCC1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.27e-05	0.00178	CbGpPWpGaD
Daunorubicin—Nausea—Cisplatin—testicular cancer	1.27e-05	0.000383	CcSEcCtD
Daunorubicin—Alopecia—Doxorubicin—testicular cancer	1.26e-05	0.000381	CcSEcCtD
Daunorubicin—CYP1A2—Biological oxidations—HPGDS—testicular cancer	1.25e-05	0.00176	CbGpPWpGaD
Daunorubicin—Cough—Methotrexate—testicular cancer	1.25e-05	0.000378	CcSEcCtD
Daunorubicin—Ill-defined disorder—Epirubicin—testicular cancer	1.24e-05	0.000377	CcSEcCtD
Daunorubicin—Convulsion—Methotrexate—testicular cancer	1.24e-05	0.000376	CcSEcCtD
Daunorubicin—Vomiting—Etoposide—testicular cancer	1.24e-05	0.000376	CcSEcCtD
Daunorubicin—Erythema—Doxorubicin—testicular cancer	1.24e-05	0.000375	CcSEcCtD
Daunorubicin—Anaemia—Epirubicin—testicular cancer	1.24e-05	0.000375	CcSEcCtD
Daunorubicin—Agitation—Epirubicin—testicular cancer	1.23e-05	0.000373	CcSEcCtD
Daunorubicin—Rash—Etoposide—testicular cancer	1.23e-05	0.000373	CcSEcCtD
Daunorubicin—Dermatitis—Etoposide—testicular cancer	1.23e-05	0.000372	CcSEcCtD
Daunorubicin—CYP1B1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.23e-05	0.00173	CbGpPWpGaD
Daunorubicin—Headache—Etoposide—testicular cancer	1.22e-05	0.00037	CcSEcCtD
Daunorubicin—Chest pain—Methotrexate—testicular cancer	1.22e-05	0.000369	CcSEcCtD
Daunorubicin—Arthralgia—Methotrexate—testicular cancer	1.22e-05	0.000369	CcSEcCtD
Daunorubicin—Myalgia—Methotrexate—testicular cancer	1.22e-05	0.000369	CcSEcCtD
Daunorubicin—Dysgeusia—Doxorubicin—testicular cancer	1.21e-05	0.000368	CcSEcCtD
Daunorubicin—Malaise—Epirubicin—testicular cancer	1.21e-05	0.000366	CcSEcCtD
Daunorubicin—Discomfort—Methotrexate—testicular cancer	1.2e-05	0.000365	CcSEcCtD
Daunorubicin—Syncope—Epirubicin—testicular cancer	1.2e-05	0.000364	CcSEcCtD
Daunorubicin—Leukopenia—Epirubicin—testicular cancer	1.2e-05	0.000363	CcSEcCtD
Daunorubicin—Back pain—Doxorubicin—testicular cancer	1.2e-05	0.000363	CcSEcCtD
Daunorubicin—Palpitations—Epirubicin—testicular cancer	1.18e-05	0.000359	CcSEcCtD
Daunorubicin—Confusional state—Methotrexate—testicular cancer	1.18e-05	0.000357	CcSEcCtD
Daunorubicin—Loss of consciousness—Epirubicin—testicular cancer	1.18e-05	0.000357	CcSEcCtD
Daunorubicin—Cough—Epirubicin—testicular cancer	1.17e-05	0.000354	CcSEcCtD
Daunorubicin—Anaphylactic shock—Methotrexate—testicular cancer	1.17e-05	0.000354	CcSEcCtD
Daunorubicin—Convulsion—Epirubicin—testicular cancer	1.16e-05	0.000352	CcSEcCtD
Daunorubicin—Infection—Methotrexate—testicular cancer	1.16e-05	0.000352	CcSEcCtD
Daunorubicin—Nausea—Etoposide—testicular cancer	1.16e-05	0.000351	CcSEcCtD
Daunorubicin—Hypertension—Epirubicin—testicular cancer	1.16e-05	0.00035	CcSEcCtD
Daunorubicin—Ill-defined disorder—Doxorubicin—testicular cancer	1.15e-05	0.000348	CcSEcCtD
Daunorubicin—Anaemia—Doxorubicin—testicular cancer	1.15e-05	0.000347	CcSEcCtD
Daunorubicin—Thrombocytopenia—Methotrexate—testicular cancer	1.14e-05	0.000347	CcSEcCtD
Daunorubicin—Arthralgia—Epirubicin—testicular cancer	1.14e-05	0.000345	CcSEcCtD
Daunorubicin—Chest pain—Epirubicin—testicular cancer	1.14e-05	0.000345	CcSEcCtD
Daunorubicin—Myalgia—Epirubicin—testicular cancer	1.14e-05	0.000345	CcSEcCtD
Daunorubicin—Agitation—Doxorubicin—testicular cancer	1.14e-05	0.000345	CcSEcCtD
Daunorubicin—Anxiety—Epirubicin—testicular cancer	1.14e-05	0.000344	CcSEcCtD
Daunorubicin—Hyperhidrosis—Methotrexate—testicular cancer	1.13e-05	0.000342	CcSEcCtD
Daunorubicin—Discomfort—Epirubicin—testicular cancer	1.13e-05	0.000341	CcSEcCtD
Daunorubicin—Malaise—Doxorubicin—testicular cancer	1.12e-05	0.000339	CcSEcCtD
Daunorubicin—Dry mouth—Epirubicin—testicular cancer	1.12e-05	0.000338	CcSEcCtD
Daunorubicin—Anorexia—Methotrexate—testicular cancer	1.11e-05	0.000337	CcSEcCtD
Daunorubicin—Syncope—Doxorubicin—testicular cancer	1.11e-05	0.000337	CcSEcCtD
Daunorubicin—Leukopenia—Doxorubicin—testicular cancer	1.11e-05	0.000336	CcSEcCtD
Daunorubicin—Confusional state—Epirubicin—testicular cancer	1.1e-05	0.000334	CcSEcCtD
Daunorubicin—Palpitations—Doxorubicin—testicular cancer	1.1e-05	0.000332	CcSEcCtD
Daunorubicin—Oedema—Epirubicin—testicular cancer	1.09e-05	0.000331	CcSEcCtD
Daunorubicin—Anaphylactic shock—Epirubicin—testicular cancer	1.09e-05	0.000331	CcSEcCtD
Daunorubicin—Loss of consciousness—Doxorubicin—testicular cancer	1.09e-05	0.00033	CcSEcCtD
Daunorubicin—Infection—Epirubicin—testicular cancer	1.09e-05	0.000329	CcSEcCtD
Daunorubicin—Cough—Doxorubicin—testicular cancer	1.08e-05	0.000328	CcSEcCtD
Daunorubicin—Shock—Epirubicin—testicular cancer	1.08e-05	0.000326	CcSEcCtD
Daunorubicin—Convulsion—Doxorubicin—testicular cancer	1.07e-05	0.000325	CcSEcCtD
Daunorubicin—Thrombocytopenia—Epirubicin—testicular cancer	1.07e-05	0.000324	CcSEcCtD
Daunorubicin—Hypertension—Doxorubicin—testicular cancer	1.07e-05	0.000324	CcSEcCtD
Daunorubicin—Tachycardia—Epirubicin—testicular cancer	1.07e-05	0.000323	CcSEcCtD
Daunorubicin—Musculoskeletal discomfort—Methotrexate—testicular cancer	1.06e-05	0.000322	CcSEcCtD
Daunorubicin—Hyperhidrosis—Epirubicin—testicular cancer	1.06e-05	0.00032	CcSEcCtD
Daunorubicin—Insomnia—Methotrexate—testicular cancer	1.06e-05	0.00032	CcSEcCtD
Daunorubicin—Arthralgia—Doxorubicin—testicular cancer	1.06e-05	0.00032	CcSEcCtD
Daunorubicin—Myalgia—Doxorubicin—testicular cancer	1.06e-05	0.00032	CcSEcCtD
Daunorubicin—Chest pain—Doxorubicin—testicular cancer	1.06e-05	0.00032	CcSEcCtD
Daunorubicin—Anxiety—Doxorubicin—testicular cancer	1.05e-05	0.000319	CcSEcCtD
Daunorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	1.05e-05	0.00148	CbGpPWpGaD
Daunorubicin—Discomfort—Doxorubicin—testicular cancer	1.04e-05	0.000316	CcSEcCtD
Daunorubicin—Anorexia—Epirubicin—testicular cancer	1.04e-05	0.000316	CcSEcCtD
Daunorubicin—Dyspnoea—Methotrexate—testicular cancer	1.04e-05	0.000316	CcSEcCtD
Daunorubicin—Somnolence—Methotrexate—testicular cancer	1.04e-05	0.000315	CcSEcCtD
Daunorubicin—Dry mouth—Doxorubicin—testicular cancer	1.03e-05	0.000313	CcSEcCtD
Daunorubicin—Confusional state—Doxorubicin—testicular cancer	1.02e-05	0.000309	CcSEcCtD
Daunorubicin—XDH—Metabolism—HPGDS—testicular cancer	1.02e-05	0.00143	CbGpPWpGaD
Daunorubicin—Decreased appetite—Methotrexate—testicular cancer	1.02e-05	0.000308	CcSEcCtD
Daunorubicin—Oedema—Doxorubicin—testicular cancer	1.01e-05	0.000306	CcSEcCtD
Daunorubicin—Anaphylactic shock—Doxorubicin—testicular cancer	1.01e-05	0.000306	CcSEcCtD
Daunorubicin—Fatigue—Methotrexate—testicular cancer	1.01e-05	0.000305	CcSEcCtD
Daunorubicin—Infection—Doxorubicin—testicular cancer	1.01e-05	0.000304	CcSEcCtD
Daunorubicin—Pain—Methotrexate—testicular cancer	1e-05	0.000303	CcSEcCtD
Daunorubicin—Musculoskeletal discomfort—Epirubicin—testicular cancer	9.97e-06	0.000302	CcSEcCtD
Daunorubicin—Shock—Doxorubicin—testicular cancer	9.96e-06	0.000301	CcSEcCtD
Daunorubicin—Thrombocytopenia—Doxorubicin—testicular cancer	9.91e-06	0.0003	CcSEcCtD
Daunorubicin—Insomnia—Epirubicin—testicular cancer	9.89e-06	0.0003	CcSEcCtD
Daunorubicin—Tachycardia—Doxorubicin—testicular cancer	9.88e-06	0.000299	CcSEcCtD
Daunorubicin—Hyperhidrosis—Doxorubicin—testicular cancer	9.79e-06	0.000296	CcSEcCtD
Daunorubicin—Dyspnoea—Epirubicin—testicular cancer	9.75e-06	0.000295	CcSEcCtD
Daunorubicin—Somnolence—Epirubicin—testicular cancer	9.72e-06	0.000294	CcSEcCtD
Daunorubicin—CYP3A4—Biological oxidations—HPGDS—testicular cancer	9.68e-06	0.00136	CbGpPWpGaD
Daunorubicin—Anorexia—Doxorubicin—testicular cancer	9.65e-06	0.000292	CcSEcCtD
Daunorubicin—Feeling abnormal—Methotrexate—testicular cancer	9.63e-06	0.000292	CcSEcCtD
Daunorubicin—Gastrointestinal pain—Methotrexate—testicular cancer	9.56e-06	0.000289	CcSEcCtD
Daunorubicin—Decreased appetite—Epirubicin—testicular cancer	9.51e-06	0.000288	CcSEcCtD
Daunorubicin—Fatigue—Epirubicin—testicular cancer	9.43e-06	0.000286	CcSEcCtD
Daunorubicin—Constipation—Epirubicin—testicular cancer	9.35e-06	0.000283	CcSEcCtD
Daunorubicin—Pain—Epirubicin—testicular cancer	9.35e-06	0.000283	CcSEcCtD
Daunorubicin—Urticaria—Methotrexate—testicular cancer	9.29e-06	0.000281	CcSEcCtD
Daunorubicin—Abdominal pain—Methotrexate—testicular cancer	9.24e-06	0.00028	CcSEcCtD
Daunorubicin—Body temperature increased—Methotrexate—testicular cancer	9.24e-06	0.00028	CcSEcCtD
Daunorubicin—Musculoskeletal discomfort—Doxorubicin—testicular cancer	9.22e-06	0.000279	CcSEcCtD
Daunorubicin—Insomnia—Doxorubicin—testicular cancer	9.15e-06	0.000277	CcSEcCtD
Daunorubicin—Dyspnoea—Doxorubicin—testicular cancer	9.02e-06	0.000273	CcSEcCtD
Daunorubicin—Feeling abnormal—Epirubicin—testicular cancer	9.01e-06	0.000273	CcSEcCtD
Daunorubicin—Somnolence—Doxorubicin—testicular cancer	9e-06	0.000272	CcSEcCtD
Daunorubicin—Gastrointestinal pain—Epirubicin—testicular cancer	8.95e-06	0.000271	CcSEcCtD
Daunorubicin—Decreased appetite—Doxorubicin—testicular cancer	8.8e-06	0.000266	CcSEcCtD
Daunorubicin—Fatigue—Doxorubicin—testicular cancer	8.73e-06	0.000264	CcSEcCtD
Daunorubicin—Urticaria—Epirubicin—testicular cancer	8.69e-06	0.000263	CcSEcCtD
Daunorubicin—Constipation—Doxorubicin—testicular cancer	8.66e-06	0.000262	CcSEcCtD
Daunorubicin—Pain—Doxorubicin—testicular cancer	8.66e-06	0.000262	CcSEcCtD
Daunorubicin—Abdominal pain—Epirubicin—testicular cancer	8.65e-06	0.000262	CcSEcCtD
Daunorubicin—Body temperature increased—Epirubicin—testicular cancer	8.65e-06	0.000262	CcSEcCtD
Daunorubicin—Hypersensitivity—Methotrexate—testicular cancer	8.61e-06	0.000261	CcSEcCtD
Daunorubicin—Asthenia—Methotrexate—testicular cancer	8.39e-06	0.000254	CcSEcCtD
Daunorubicin—Feeling abnormal—Doxorubicin—testicular cancer	8.34e-06	0.000253	CcSEcCtD
Daunorubicin—Gastrointestinal pain—Doxorubicin—testicular cancer	8.28e-06	0.000251	CcSEcCtD
Daunorubicin—Pruritus—Methotrexate—testicular cancer	8.27e-06	0.00025	CcSEcCtD
Daunorubicin—Hypersensitivity—Epirubicin—testicular cancer	8.06e-06	0.000244	CcSEcCtD
Daunorubicin—Urticaria—Doxorubicin—testicular cancer	8.04e-06	0.000243	CcSEcCtD
Daunorubicin—Body temperature increased—Doxorubicin—testicular cancer	8e-06	0.000242	CcSEcCtD
Daunorubicin—Abdominal pain—Doxorubicin—testicular cancer	8e-06	0.000242	CcSEcCtD
Daunorubicin—Diarrhoea—Methotrexate—testicular cancer	8e-06	0.000242	CcSEcCtD
Daunorubicin—Asthenia—Epirubicin—testicular cancer	7.85e-06	0.000238	CcSEcCtD
Daunorubicin—Pruritus—Epirubicin—testicular cancer	7.74e-06	0.000234	CcSEcCtD
Daunorubicin—Dizziness—Methotrexate—testicular cancer	7.73e-06	0.000234	CcSEcCtD
Daunorubicin—CYP1A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	7.55e-06	0.00106	CbGpPWpGaD
Daunorubicin—ABCB11—Metabolism—HPGDS—testicular cancer	7.52e-06	0.00106	CbGpPWpGaD
Daunorubicin—Diarrhoea—Epirubicin—testicular cancer	7.48e-06	0.000227	CcSEcCtD
Daunorubicin—Hypersensitivity—Doxorubicin—testicular cancer	7.46e-06	0.000226	CcSEcCtD
Daunorubicin—Vomiting—Methotrexate—testicular cancer	7.43e-06	0.000225	CcSEcCtD
Daunorubicin—XDH—Metabolism—STK11—testicular cancer	7.41e-06	0.00104	CbGpPWpGaD
Daunorubicin—Rash—Methotrexate—testicular cancer	7.37e-06	0.000223	CcSEcCtD
Daunorubicin—Dermatitis—Methotrexate—testicular cancer	7.36e-06	0.000223	CcSEcCtD
Daunorubicin—Headache—Methotrexate—testicular cancer	7.32e-06	0.000222	CcSEcCtD
Daunorubicin—Asthenia—Doxorubicin—testicular cancer	7.26e-06	0.00022	CcSEcCtD
Daunorubicin—Dizziness—Epirubicin—testicular cancer	7.23e-06	0.000219	CcSEcCtD
Daunorubicin—Pruritus—Doxorubicin—testicular cancer	7.16e-06	0.000217	CcSEcCtD
Daunorubicin—Vomiting—Epirubicin—testicular cancer	6.96e-06	0.000211	CcSEcCtD
Daunorubicin—Nausea—Methotrexate—testicular cancer	6.94e-06	0.00021	CcSEcCtD
Daunorubicin—Diarrhoea—Doxorubicin—testicular cancer	6.93e-06	0.00021	CcSEcCtD
Daunorubicin—Rash—Epirubicin—testicular cancer	6.9e-06	0.000209	CcSEcCtD
Daunorubicin—Dermatitis—Epirubicin—testicular cancer	6.89e-06	0.000209	CcSEcCtD
Daunorubicin—Headache—Epirubicin—testicular cancer	6.85e-06	0.000207	CcSEcCtD
Daunorubicin—Dizziness—Doxorubicin—testicular cancer	6.69e-06	0.000203	CcSEcCtD
Daunorubicin—Nausea—Epirubicin—testicular cancer	6.5e-06	0.000197	CcSEcCtD
Daunorubicin—Vomiting—Doxorubicin—testicular cancer	6.44e-06	0.000195	CcSEcCtD
Daunorubicin—Rash—Doxorubicin—testicular cancer	6.38e-06	0.000193	CcSEcCtD
Daunorubicin—Dermatitis—Doxorubicin—testicular cancer	6.38e-06	0.000193	CcSEcCtD
Daunorubicin—Headache—Doxorubicin—testicular cancer	6.34e-06	0.000192	CcSEcCtD
Daunorubicin—Nausea—Doxorubicin—testicular cancer	6.01e-06	0.000182	CcSEcCtD
Daunorubicin—ABCC1—Metabolism—HPGDS—testicular cancer	5.65e-06	0.000794	CbGpPWpGaD
Daunorubicin—ABCB11—Metabolism—STK11—testicular cancer	5.46e-06	0.000768	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism—HPGDS—testicular cancer	5.46e-06	0.000768	CbGpPWpGaD
Daunorubicin—ABCG2—Metabolism—HPGDS—testicular cancer	4.97e-06	0.000699	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—H2AFZ—testicular cancer	4.93e-06	0.000693	CbGpPWpGaD
Daunorubicin—SLC22A2—Metabolism—HPGDS—testicular cancer	4.92e-06	0.000692	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	4.82e-06	0.000678	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—KITLG—testicular cancer	4.53e-06	0.000638	CbGpPWpGaD
Daunorubicin—ABCC1—Metabolism—STK11—testicular cancer	4.1e-06	0.000577	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism—STK11—testicular cancer	3.97e-06	0.000558	CbGpPWpGaD
Daunorubicin—ABCG2—Metabolism—STK11—testicular cancer	3.61e-06	0.000508	CbGpPWpGaD
Daunorubicin—SLC22A2—Metabolism—STK11—testicular cancer	3.57e-06	0.000503	CbGpPWpGaD
Daunorubicin—CYP3A5—Metabolism—HPGDS—testicular cancer	3.56e-06	0.000501	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—FGFR3—testicular cancer	3.37e-06	0.000474	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism—HPGDS—testicular cancer	3.36e-06	0.000473	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—KIT—testicular cancer	3.09e-06	0.000435	CbGpPWpGaD
Daunorubicin—ABCB1—Metabolism—HPGDS—testicular cancer	2.69e-06	0.000378	CbGpPWpGaD
Daunorubicin—CYP3A5—Metabolism—STK11—testicular cancer	2.59e-06	0.000364	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism—STK11—testicular cancer	2.44e-06	0.000344	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism—HPGDS—testicular cancer	2.14e-06	0.000302	CbGpPWpGaD
Daunorubicin—ABCB1—Metabolism—STK11—testicular cancer	1.95e-06	0.000275	CbGpPWpGaD
Daunorubicin—CYP3A4—Metabolism—HPGDS—testicular cancer	1.66e-06	0.000233	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism—STK11—testicular cancer	1.56e-06	0.000219	CbGpPWpGaD
Daunorubicin—CYP3A4—Metabolism—STK11—testicular cancer	1.2e-06	0.000169	CbGpPWpGaD
